Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched.
A groundbreaking observational study is set to investigate the real-world efficacy of MDMA-assisted therapy through Health Canada’s Special Access Programme (SAP).
New findings on psychedelics will be presented at Neuroscience 2023, the annual meeting of the Society for Neuroscience, on Tuesday, 14 November.
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s...
Cybin Inc.
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Mind Medicine has confirmed it has completed enrollment of Study MMED007, its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of...
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT...
The Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics.